← Back to Search

Exercise Training for Depression in Multiple Sclerosis (METS in MS Trial)

N/A
Recruiting
Led By Robert W Motl, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of Major Depressive Disorder (MDD) as per MINI
Age between 18 and 64 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (week 0), immediate follow-up (week 16 or 4 months), and long-term follow-up (week 32 or 8 months)
Awards & highlights

METS in MS Trial Summary

This trial will study the effects of different exercise training regimens on depression symptoms and other health indicators in people with MS & MDD.

Who is the study for?
This trial is for people aged 18-64 with Multiple Sclerosis (MS) and Major Depressive Disorder (MDD), who have internet access, speak English, and are willing to participate in exercise testing. They must not have had a relapse or taken steroids recently, should be relatively inactive based on specific questionnaires, and cannot have certain severe mental illnesses.Check my eligibility
What is being tested?
The study compares two exercise programs for reducing depression in MS patients: POWER-MS (an exercise training program) versus FLEX-MS (a stretching program). It aims to see which one better decreases the severity of depression immediately and over time.See study design
What are the potential side effects?
While the trial primarily involves physical activity regimens that typically do not cause severe side effects, participants may experience muscle soreness or fatigue related to increased physical activity.

METS in MS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Major Depressive Disorder.
Select...
I am between 18 and 64 years old.
Select...
I have been diagnosed with Multiple Sclerosis.

METS in MS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (week 0), immediate follow-up (week 16 or 4 months), and long-term follow-up (week 32 or 8 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (week 0), immediate follow-up (week 16 or 4 months), and long-term follow-up (week 32 or 8 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Depression Severity (observer-rated)
Change in Depression Severity (self-report)
Secondary outcome measures
Change in Cognitive Performance
Change in Perception of Fatigue Severity
Change in Quality of Life
Other outcome measures
Change in Aerobic Capacity
Change in Muscle Strength
Change in Physical Activity
+1 more

METS in MS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: POWER-MSExperimental Treatment1 Intervention
The POWER-MS condition will deliver the Guidelines for Exercise in MS (GEMS) program with a remotely coached/guided, home-based setting using telerehabilitation. GEMS recommends 30 minutes of moderate intensity aerobic activity, 3x/week AND strength training exercises for major muscle groups, 3x/week.
Group II: FLEX-MSActive Control1 Intervention
The FLEX-MS condition will primarily focus on flexibility as the applicable exercise modality. As such, the program will emphasize that flexibility is an important component of fitness. The goal would be for each participant to enhance their flexibility by engaging in a titrated exercise prescription where the number of sets and time to hold per set will increase throughout the 16-week program.

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
603 Previous Clinical Trials
1,558,405 Total Patients Enrolled
11 Trials studying Multiple Sclerosis
1,390 Patients Enrolled for Multiple Sclerosis
Congressionally Directed Medical Research ProgramsFED
46 Previous Clinical Trials
6,893 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,571 Previous Clinical Trials
2,268,865 Total Patients Enrolled
37 Trials studying Multiple Sclerosis
45,137 Patients Enrolled for Multiple Sclerosis

Media Library

FLEX-MS Clinical Trial Eligibility Overview. Trial Name: NCT05051618 — N/A
Multiple Sclerosis Research Study Groups: FLEX-MS, POWER-MS
Multiple Sclerosis Clinical Trial 2023: FLEX-MS Highlights & Side Effects. Trial Name: NCT05051618 — N/A
FLEX-MS 2023 Treatment Timeline for Medical Study. Trial Name: NCT05051618 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are the age stipulations for this clinical trial allowing participants under eighty years of age?

"As identified in the selection criteria, potential participants must be within 18 and 64 years old."

Answered by AI

Am I able to partake in this experiment?

"Applicants with a diagnosis of multiple sclerosis and aged 18 to 64 are eligible for this study, which is offering admission to 146 patients."

Answered by AI

How many participants has this research endeavor recruited thus far?

"Indeed, according to clinicaltrials.gov this medical study is still recruiting patients. The trial was first published on April 1st 2023 and the most recent update occured on April 4th of the same year. Currently, 146 participants are needed from a single location."

Answered by AI

Is there room for additional participants in this trial?

"Yes, according to clinicaltrials.gov this trial is still recruiting participants. Launched on April 1st 2023, the study aims to enrol 146 individuals from a single medical facility."

Answered by AI
~76 spots leftby Mar 2025